Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 1Phase 2 Interventional

A Study of YL201 in Patients With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT05434234

Public ClinicalTrials.gov record NCT05434234. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 6, 2026, 4:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1A/1B, Multicenter, Nonrandomized, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL201 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohorts of patients with advanced solid tumors unresponsive to currently available therapies or for whom no standard therapy is available. Part 2 will include patients with selected advanced solid tumor types enrolled at the MTD/RED(s), to better define the safety profile and evaluate the efficacy of YL201.

Study identification

NCT ID
NCT05434234
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Enrollment
312 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 24, 2022
Primary completion
Apr 5, 2027
Completion
Oct 5, 2027
Last update posted
Jun 21, 2026

2022 – 2027

United States locations

U.S. sites
19
U.S. states
13
U.S. cities
19
Facility City State ZIP Site status
002 Fair Oaks California 95628 Recruiting
001 La Jolla California 92093-0698 Recruiting
003 Lone Tree Colorado 80124 Recruiting
004 Washington D.C. District of Columbia 20007 Recruiting
005 Boston Massachusetts 02114 Recruiting
006 Ann Arbor Michigan 48109 Recruiting
007 Detroit Michigan 48292 Recruiting
008 St Louis Missouri 63110 Recruiting
009 Santa Fe New Mexico 87505-699 Recruiting
010 New York New York 10029 Recruiting
011 Chapel Hill North Carolina 27514 Recruiting
012 Nashville Tennessee 37203 Recruiting
014 Houston Texas 77030 Recruiting
015 Irving Texas 75039 Recruiting
013 San Antonio Texas 78229 Recruiting
016 Tyler Texas 75701 Recruiting
017 Fairfax Virginia 22031 Recruiting
018 Spokane Washington 99208 Recruiting
019 Tacoma Washington 98405 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05434234, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 21, 2026 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05434234 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →